Targeting Ferroptosis with N6022: A Potential Therapeutic Strategy for Ischemic Stroke

Stroke poses a significant mortality risk, particularly in the elderly population. The global rise in aging has propelled stroke to the forefront of health concerns, demanding urgent attention and intervention. Ischemic stroke, characterized by a disruption of blood flow to the brain, involves a complex pathophysiological process. Understanding the molecular mechanisms underlying ischemic stroke is crucial for developing effective therapies. Ferroptosis, a recently identified form of programmed cell death distinct from necrosis, apoptosis, and autophagy, has emerged as a key player in the pathogenesis of ischemic stroke. Studies have shown promising neuroprotective effects by targeting ferroptosis after ischemia/reperfusion (I/R). N6022, a 'first-in-class' drug and a selective inhibitor of GSNOR, holds potential therapeutic value. GSNOR dysregulation has been linked to various diseases, including cancer, asthma, and cardiac ischemic diseases. By inhibiting GSNOR, N6022 may offer a novel approach to mitigate the damaging effects of ferroptosis in ischemic stroke.